

082-35057



07022070



RECEIVED

2007 APR -2 A 9:21



Technology Pioneer 2007

PROCESSED

APR 06 2007

OFFICE OF INTERNATIONAL CORPORATE FINANCE

SUPPL

NEWS RELEASE FOR IMMEDIATE RELEASE

THOMSON FINANCIAL

TSX Venture: AMF

**AMORFIX PROVIDES CORPORATE UPDATE ON THERAPEUTICS PROGRAM FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS or LOU GEHRIG'S DISEASE)**

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Ontario – March 23, 2007 – Amorfix Life Sciences Ltd. (TSX-V:AMF), a theranostics company developing diagnostics and treatments for aggregated misfolded protein (AMP) related diseases, today announced Dr. Neil Cashman, Chief Scientific Officer of Amorfix will be presenting a study entitled "Immunotherapy of ALS" at the ALS Canada Research Conference in Toronto, on March 25, 2007. The study is based on pioneering work by Dr. Cashman and shows for the first time promising animal studies that a targeted immunotherapy approach may lead to an effective treatment for this debilitating disease.

Dr. Cashman has long proposed that the misfolding and aggregation of superoxide dismutase 1 (SOD1), which is known to occur in familial ALS patients, is a principal agent in the death of motor neurons in all types of ALS disease. He hypothesized, 5 years ago, that if the misfolded SOD1 could be recognized and neutralized by the immune system prior to aggregation, the disease could be effectively treated. The animal studies provide early but provocative data supporting this approach.

These studies were conducted as part of the research collaboration with Biogen Idec (NASDAQ: BIIB) of Cambridge, Massachusetts. The collaboration includes an option for Biogen Idec to license the exclusive worldwide rights to Amorfix's technology to develop and commercialize therapeutic products directed against ALS.

"These results, while still very early, demonstrate the potential of targeted immunotherapy as a novel approach for the effective treatment of ALS," said Dr. George Adams, President and Chief Executive Officer of Amorfix. "We continue to advance our therapeutic program for AMP diseases, specifically in relation to our research collaboration with Biogen Idec targeting ALS. There are a number of milestones remaining and we are making excellent progress."

Amorfix is also announcing that it has filed an international patent application entitled "Methods and Compositions to Treat and Detect Misfolded-SOD1 Mediated Diseases". The Company is continuing to expand its intellectual property estate based on initiatives generated by its therapeutics research and development program.

**About Amorfix**

Amorfix is an emerging biotechnology company focused on the diagnosis and treatment of brain-wasting diseases, where aggregated misfolded proteins (AMPs) are prevalent. These

*Dee 4/2*

include "prions", the infectious agents of the Transmissible Spongiform Encephalopathies (TSE), such as BSE and variant CJD, as well as degenerative diseases such as Alzheimer's Disease, ALS and Parkinson's Disease. Amorfix is focused on discovering and commercializing technologies to become the world leader on AMP diseases. The company will use this knowledge to develop diagnostic kits, treatments and vaccines for AMP diseases.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

- 30 -

**For more information, please contact:**

<p>Dr. George Adams            President &amp; Chief Operating Officer            Amorfix Life Sciences Ltd.            Tel: (416) 482-3813            Fax: (416) 482-3811  <a href="mailto:george.adams@amorfix.com">george.adams@amorfix.com</a></p>	<p>James Parsons            Chief Financial Officer            Amorfix Life Sciences Ltd.            Tel: (416) 482-3814            Fax: (416) 482-3811  <a href="mailto:james.parsons@amorfix.com">james.parsons@amorfix.com</a></p>
--	---